In the realm of neutropenia management, significant advancements arise with the advent of Ziextenzo. This biosimilar filgrastim serves as a powerful tool against neutropenia. Neutropenia, marked by a critical decrease in neutrophils, presents grave risks for patients undergoing intensive treatments. Vulnerability to infections and complications necessitates robust strategies. Ziextenzo emerges as a prominent player in…